CR-3022

N/A

Report date: 2022/07/01 15:29:28

Base Information

Drug NameCR-3022
Drug Alias NameCR-3022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Coronavirus spike glycoprotein
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsSevere Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson
Inactive CompaniesN/A
Active IndicationsSevere Acute Respiratory Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A